Post-IPO Equity - Ascentage Pharma
Investment Firm
Overview
Ascentage is a clinical-stage biopharmaceutical company that develops drugs for the treatment of cancer.
Announced Date
Jun 20, 2024
Closed on Date
Jun 20, 2024
Funding Type
Post Ipo Equity
Highlights
Location
Asia
Social
Investor Lead
Participant Investors
1
| Investor Name |
|---|
 Takeda |
Round Details and Background
Ascentage Pharma raised $75000000 on 2024-06-20 in Post-IPO Equity
Ascentage is a clinical-stage biopharmaceutical company that develops drugs for the treatment of cancer.
Company Funding History
4
| Announcment Date | Transaction Name | Number Of Investors | Lead Investor | Money Raised |
|---|---|---|---|---|
| Jul 17, 2018 |  Series C - Ascentage Pharma | 7 | - | 150.0M |
| Jun 20, 2024 | Post-IPO Equity - Ascentage Pharma | 1 | - | 75.0M |
| Dec 26, 2016 | Series B - Ascentage Pharma | 4 | - | 72.0M |
| Aug 14, 2015 | Series A - Ascentage Pharma | 5 | - | 15.5M |
Recent Activity
There is no recent news or activity for this profile.